Reference SummaryTakahashi O, Toxicology 1997 Dec 26;124(2):95-103

Title

 Chronic toxicity studies of piperonyl butoxide in CD-1 mice: induction of hepatocellular carcinoma.

Authors

 Takahashi O; Oishi S; Fujitani T; Tanaka T; Yoneyama M

Journal

 Toxicology

Volume

 124

Issue

 2

Year

 1997

Pages

 95-103

Abstract

 Male and female CD-1 mice (51-104 mice/group) were administered piperonyl butoxide (alpha-[2-(2-butoxyethoxy)ethoxy-4,5-methylenedioxy-2-propyltol uene) in the diet at levels of 0 (control), 0.6 and 1.2% for 52 weeks (1 year). Hepatocellular carcinomas were induced in treated groups in a dose-dependent manner. The incidences of hepatocellular carcinoma were 11.3 and 52.0% in male mice given 0.6 and 1.2% piperonyl butoxide, and 41.2% in female mice given 1.2%. Piperonyl butoxide is thus a hepatocarcinogen to mice as it is known to be to rats.

Links

 J:46037 – MGI References
9457999 – National Library of Medicine/PubMed

Strain Notes

Strain Note
CD-1 These mice were purchased from Charles River Japan.

Models
Strain Model Name Treatment Agent(s) Organ Affected Frequency Model Details
CD-1 Blood vessel hemangiosarcoma Liver

0
CD-1 Blood vessel hemangiosarcoma
  • piperonyl butoxide (alpha-[2-(2-butoxyethoxy)ethoxy-4,5-methylenedioxy-2-propyltoluene)
 Liver

0 - 80
CD-1 Bulbourethral gland adenoma Bulbourethral gland

2.0
CD-1 Leukocyte lymphoma Leukocyte

low
CD-1 Leukocyte lymphoma
  • piperonyl butoxide (alpha-[2-(2-butoxyethoxy)ethoxy-4,5-methylenedioxy-2-propyltoluene)
 Leukocyte

low
CD-1 Liver - Bile duct cholangioma Liver - Bile duct

0 - 2.0
CD-1 Liver - Bile duct cholangioma
  • piperonyl butoxide (alpha-[2-(2-butoxyethoxy)ethoxy-4,5-methylenedioxy-2-propyltoluene)
 Liver - Bile duct

0 - 1.6
CD-1 Liver - Hepatocyte hyperplasia Liver - Hepatocyte

0 - 2.0
CD-1 Liver - Hepatocyte hyperplasia
  • piperonyl butoxide (alpha-[2-(2-butoxyethoxy)ethoxy-4,5-methylenedioxy-2-propyltoluene)
 Liver - Hepatocyte

9.9 - 38
CD-1 Liver hepatocellular adenoma Liver

0 - 2.0
CD-1 Liver hepatocellular adenoma
  • piperonyl butoxide (alpha-[2-(2-butoxyethoxy)ethoxy-4,5-methylenedioxy-2-propyltoluene)
 Liver

0 - 26
CD-1 Liver hepatocellular carcinoma Liver

0
CD-1 Liver hepatocellular carcinoma
  • piperonyl butoxide (alpha-[2-(2-butoxyethoxy)ethoxy-4,5-methylenedioxy-2-propyltoluene)
 Liver

0 - 80
CD-1 Lung adenoma Lung

2.0 - very low
CD-1 Lung adenoma
  • piperonyl butoxide (alpha-[2-(2-butoxyethoxy)ethoxy-4,5-methylenedioxy-2-propyltoluene)
 Lung

very low
CD-1 Urinary bladder tumor Urinary bladder

2.0